TY - JOUR
T1 - Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli
AU - Kussmann, Manuel
AU - Schuster, Linda
AU - Wrenger, Sarah
AU - Pichler, Petra
AU - Reznicek, Gottfried
AU - Burgmann, Heinz
AU - Poeppl, Wolfgang
AU - Zeitlinger, Markus
AU - Wiesholzer, Martin
N1 - Publisher Copyright:
© 2016 International Society for Peritoneal Dialysis.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - ♦ BACKGROUND: Peritonitis is a major problem among patients on peritoneal dialysis (PD). The influence of diverse PD fluids on the activity of frequently used antibiotics has been insufficiently investigated. Thus, the present study set out to investigate the impact of different PD fluids on the activity of cefepime, ciprofloxacin, ertapenem, meropenem, and tobramycin against Escherichia coli. ♦ METHODS: Time-kill curves in 4 different PD fluids (Dianeal PDG4, Extraneal, Nutrineal PD4 and Physioneal 40, all Baxter Healthcare Corp., Deerfield, IL, USA) were performed over 24 hours with 4 different concentrations (1 × minimum inhibitory concentration [MIC], 4 × MIC, 8 × MIC, 30 × MIC) of each antibiotic evaluated and without antibiotics as control. Cation-adjusted Mueller Hinton broth (CA-MHB) was used as comparator solution. ♦ RESULTS: In all PD fluids investigated, bacterial growth and antimicrobial activity of all antibiotics tested was significantly reduced compared with the CA-MHB comparator solution. Except at high concentrations of 30 × MIC, cefepime, ertapenem and meropenem demonstrated a strongly reduced activity in all PD fluids investigated. Ciprofloxacin and tobramycin were highly active and bactericidal in all PD fluids and demonstrated dose-dependent activity. ♦ CONCLUSION: The antimicrobial activity of cefepime, ertapenem and meropenem is limited or even nullified in certain PD fluids in vitro, whereas ciprofloxacin and tobramycin show excellent activity. The choice of PD fluids can impact the activity of antimicrobial agents and might influence microbiological outcome. Further studies are required to verify the clinical relevance of our findings.
AB - ♦ BACKGROUND: Peritonitis is a major problem among patients on peritoneal dialysis (PD). The influence of diverse PD fluids on the activity of frequently used antibiotics has been insufficiently investigated. Thus, the present study set out to investigate the impact of different PD fluids on the activity of cefepime, ciprofloxacin, ertapenem, meropenem, and tobramycin against Escherichia coli. ♦ METHODS: Time-kill curves in 4 different PD fluids (Dianeal PDG4, Extraneal, Nutrineal PD4 and Physioneal 40, all Baxter Healthcare Corp., Deerfield, IL, USA) were performed over 24 hours with 4 different concentrations (1 × minimum inhibitory concentration [MIC], 4 × MIC, 8 × MIC, 30 × MIC) of each antibiotic evaluated and without antibiotics as control. Cation-adjusted Mueller Hinton broth (CA-MHB) was used as comparator solution. ♦ RESULTS: In all PD fluids investigated, bacterial growth and antimicrobial activity of all antibiotics tested was significantly reduced compared with the CA-MHB comparator solution. Except at high concentrations of 30 × MIC, cefepime, ertapenem and meropenem demonstrated a strongly reduced activity in all PD fluids investigated. Ciprofloxacin and tobramycin were highly active and bactericidal in all PD fluids and demonstrated dose-dependent activity. ♦ CONCLUSION: The antimicrobial activity of cefepime, ertapenem and meropenem is limited or even nullified in certain PD fluids in vitro, whereas ciprofloxacin and tobramycin show excellent activity. The choice of PD fluids can impact the activity of antimicrobial agents and might influence microbiological outcome. Further studies are required to verify the clinical relevance of our findings.
KW - Anti-Bacterial Agents/pharmacology
KW - Cefepime
KW - Cephalosporins/pharmacology
KW - Ciprofloxacin/pharmacology
KW - Dialysis Solutions/adverse effects
KW - Ertapenem
KW - Escherichia coli/drug effects
KW - Humans
KW - In Vitro Techniques
KW - Meropenem
KW - Microbial Sensitivity Tests
KW - Peritoneal Dialysis/adverse effects
KW - Peritonitis/drug therapy
KW - Sensitivity and Specificity
KW - Thienamycins/pharmacology
KW - Tobramycin/pharmacology
KW - beta-Lactams/pharmacology
KW - Time-kill curves
KW - Peritoneal dialysis solutions
KW - Infection
KW - Antibiotics
KW - Peritonitis
UR - http://www.scopus.com/inward/record.url?scp=85000910591&partnerID=8YFLogxK
U2 - 10.3747/pdi.2015.00161
DO - 10.3747/pdi.2015.00161
M3 - Journal article
C2 - 27680756
SN - 0896-8608
VL - 36
SP - 662
EP - 668
JO - Peritoneal Dialysis International
JF - Peritoneal Dialysis International
IS - 6
ER -